**WHY IT IS OF IMPORTANCE TO SEEK EARL FDG-PET/CT ACCREDITATION AND HOW YOU WILL BENEFIT**

The EANM would like to emphasise the high importance of quality in nuclear medicine practice by offering special support: the EANM has committed itself to covering the costs for the first year of accreditation of PET/CT systems newly installed between 31.10.2013 and 31.10.2014 in Europe. This offer is subject to modifications and only applicable for new EARL accreditation customers. Take advantage of this extraordinary opportunity and redeem your voucher covering the accreditation fee for a calendar year, within a maximum of 6 months after installation of your PET/CT system, by contacting EARL (earl@eanm.org).

**WHAT HAPPENS IF YOUR PET/CT SYSTEM IS INSTALLED OUTSIDE OF THE TIMEFRAME 31.10.2013 TO 31.10.2014?**

The cost of participation in the accreditation programme is € 1000.- per site, per PET/CT system and per calendar year, which includes the initial accreditation process as well as all ongoing procedures. Join the accreditation programme now by registering at earl@eanm.org.

For further information, please visit [http://earl.eanm.org](http://earl.eanm.org) or contact EARL earl@eanm.org.
Independent quality control/assurance by a fully authorised body. EARL’s know-how is based on imaging experts with a worldwide reputation and a global leading role in PET/CT research, who provide advice within the programme and monitor its development.

Comparable scanner performance across multiple sites through harmonisation of the acquisition and interpretation of PET/CT scans (reducing inter/intra-institute variability in SUV results; providing lower/upper limits of recovery coefficients; calibration factor within +/-10%): results can be compared, exchanged and combined.

Accurate, reproducible and quantitative assessment enabled through standardisation of methodology, including patient preparation, scan acquisition, image processing and analysis.

Essential quality assurance in daily clinical practice as well as high eligibility as a participant in multicentre trials.

Accredited centres of excellence strengthen their status via publication in the EARL website, a signet sticker and an accreditation certificate.

In order to support compliance with requirements regarding quality control and quality assurance of PET/CT systems, the European Association of Nuclear Medicine (EANM) established the FDG-PET/CT accreditation programme in 2010 on the basis of the FDG PET and PET/CT: EANM procedure guideline for tumour PET imaging: version 1.0, published in the European Journal of Nuclear Medicine and Molecular Imaging. This programme is run by EANM Research Ltd (EARL), a 100% subsidiary of EANM, which has a strong focus on enhancing the quality of nuclear medicine clinical practice and research to the benefit of public health.

PET/CT is a powerful imaging tool for the detection of various cancers within daily clinical practice. Furthermore, it is essential in clinical and preclinical multicentre trials since molecular imaging biomarkers accelerate drug development by detecting drug activity and measuring efficacy.

In order to support compliance with requirements regarding quality control and quality assurance of PET/CT systems, the European Association of Nuclear Medicine (EANM) established the FDG-PET/CT accreditation programme in 2010 on the basis of the FDG PET and PET/CT: EANM procedure guideline for tumour PET imaging: version 1.0, published in the European Journal of Nuclear Medicine and Molecular Imaging. This programme is run by EANM Research Ltd (EARL), a 100% subsidiary of EANM, which has a strong focus on enhancing the quality of nuclear medicine clinical practice and research to the benefit of public health.

5 REASONS TO JOIN AN OUTSTANDING NETWORK OF MORE THAN 75 EARL-ACCREDITED PET/CT CENTRES OF EXCELLENCE

1. Independent quality control/assurance by a fully authorised body. EARL’s know-how is based on imaging experts with a worldwide reputation and a global leading role in PET/CT research, who provide advice within the programme and monitor its development.

2. Comparable scanner performance across multiple sites through harmonisation of the acquisition and interpretation of PET/CT scans (reducing inter/intra-institute variability in SUV results; providing lower/upper limits of recovery coefficients; calibration factor within +/-10%): results can be compared, exchanged and combined.

3. Accurate, reproducible and quantitative assessment enabled through standardisation of methodology, including patient preparation, scan acquisition, image processing and analysis.

4. Essential quality assurance in daily clinical practice as well as high eligibility as a participant in multicentre trials.

5. Accredited centres of excellence strengthen their status via publication in the EARL website, a signet sticker and an accreditation certificate.